Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

IN8bio, INAB, up 185% on Phase I testing for leukaemia drug - fundraise likely coming

Good results for IN8bio but the next stage is very likely to be a fundraise

Update : 25 Apr 2023, 02:04 PM

IN8bio (NASDAQ: INAB) stock is up 185% on yesterday on the news that their leukaemia treatment seems to be working very well. Actually, very well indeed and there's the thing we don't quite know yet. Is it working so well that development can be accelerated? There's also the obvious issue that with a validation event like this there's going to be a fundraise following right behind. That's just the way that development pharma companies work and for good reason. So, we'd probably not expect to see this stock price run away ever upward - there's going to be an event that halts it soon enough.

As background IN8bio is developing cancer treatments. Good, we need more of those. The specific details of what they're doing are here. So are the results of the trial they've just announced. For us we can simply accept that those results are very good. However, they're also only Phase I. That's early days and at the beginning of the really expensive later testing processes. We're a long way from revenue and there's much expense to be carried before that. There are - occasionally and rarely - times when the expense is greatly reduced. Which is when the results are so good that it's simply unethical to continue with double blind trials - to not give the treatment that is so obviously working for those who get it. We're not at that stage here yet but it's something to dream about still.

IN8bio stock price from NASDAQ

So, what looks like a good candidate, decent results, what happens next? Near certainly a fundraise. INAB has some $18 million in cash at the last results. It costs $28 million a year to run the company and that cost is rising - as it always does when moving out of pure research and into the actual testing process. There's no revenue, these costs have to be carried by shareholder capital. So, obviously enough, there's going to be a visit to stockholders to gain more of their capital.

This just is the way that pharma research works. Every company is funded to the next decision point, the next valuation point. Get to that, then a decision can be made about whether to continue funding to get to the next one and so on. We've got good results from Phase I trials here. Great, so funding to do more, to move to Phase II, is indicated. Therefore IN8bio is going to be coming to market soon enough, hand out, asking for more capital to keep going.

As we say, that's just how the sector works. Good results, stock price rises, new stock issue.

Top Brokers